Abstract:Background 99 Tc-MDP has been used in Chinese RA patients for over 15 years and many more studies have focused on this agent in RA. However, the previous studies limited in its effect on the effects of anti-inflammation. As a special form of bisphosphonate, the anti-osteoporotic effect of 99 Tc-MDP is unclear. Objectives To systematically investigate the effect of technetium-99 conjugated with methylene diphosphonate ( 99 Tc-MDP), an anti-inflammatory drug effective in treating rheumatoid arthritis (RA), on cortical and cancellous bones in glucocorticoid-induced osteoporotic (GIO) rats, as well as comparing the effect of 99 Tc-MDP with that of methylene diphosphonate (MDP). Methods Forty-eight Sprague-Dawley rats were randomly divided into six groups: blank, negative control, high dose, medium dose, low dose, and positive control groups. After dexamethasone was given to all groups except the blank group to induce osteoporosis, the rats in different groups were treated with saline, MDP, or different doses of Results Micro-CT analyses showed that: (1) 99 Tc-MDP reversed glucocorticoid induced bone microarchitecture destruction by increasing vBMD, BV/TV, Tb.Th, Tb.N and decreasing BS/BV, Tb.Sp and TBPf; (2) effect of 99 Tc-MDP increased as its dosage increased; and (3) 99 Tc-MDP could improve cortical bone thickness while MDP failed to do so. Micro-CT spatial structure analysis and histology also yielded consistent results, indicating 99 Tc-MDP increased trabecular number and connectivity morphologically. Finally, biomechanics revealed 99 Tc-MDP can enhance the extrinsic stiffness of bone by changing bone geometry. Conclusions 99 Tc-MDP has anti-osteoporotic effect by improving both cancellous and cortical bone, as well as increasing extrinsic bone stiffness. The dual effect of 99 Tc-MDP, anti-inflammatory and anti-osteoporotic, may suggest a potential clinical application for patients with both GIO and RA. References Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nature reviews Rheumatology 2010;6:693–702. Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 2012;51 Suppl 4:iv9–13. Acknowledgements We thank Mr. Kai Gao for providing the rats and Dr. Min Feng for assistance in histological processing of the rats. This work was supported by grants from the Natural Science Foundation of China (81501396 to Dr. Lianjie Shi, and 81302554 to Dr. Fanlei Hu). Disclosure of Interest None declared

Technetium‐99 Conjugated with Methylene Diphosphonate Inhibits Receptor Activator of Nuclear Factor‐κb Ligand‐induced Osteoclastogenesis

Technetium-99 Conjugated with Methylene Diphosphonate Inhibits RANKL-induced Osteoclastogenesis.

Mineralizing Solution and Dexamethasone Enhance Receptor Activator for NF-κB Ligand Expression in Rat Bone Marrow Stromal Cells

Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Glucocorticoid Induced Osteoporosis by Inhibiting Osteoclastogenesis

Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Ovariectomy-Induced Osteoporotic Phenotype Without Causing Osteonecrosis in the Jaw

AB0845 Technetium-99 conjugated with methylene diphosphonate ameliorates glucocorticoid induced osteoporosis in rats

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Mmp-9 Inhibition Suppresses Wear Debris-Induced Inflammatory Osteolysis Through Downregulation Of Rank/Rankl In A Murine Osteolysis Model

Methyl 3,4-dihydroxybenzoate inhibits RANKL-induced osteoclastogenesis via Nrf2 signaling in vitro and suppresses LPS-induced osteolysis and ovariectomy-induced osteoporosis in vivo

Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling

Deacylcynaropicrin Inhibits RANKL-Induced Osteoclastogenesis by Inhibiting NF-κB and MAPK and Promoting M2 Polarization of Macrophages.

The PPAR-γ Antagonist T007 Inhibits RANKL-induced Osteoclastogenesis and Counteracts OVX-induced Bone Loss in Mice

99Tc‐methylene Diphosphonate Improves Rheumatoid Arthritis Disease Activity by Increasing the Frequency of Peripheral Γδ T Cells and CD4+CD25+Foxp3+Tregs

Radiation Alters Osteoclastogenesis by Regulating the Cytoskeleton and Lytic Enzymes in RAW 264.7 Cells and Mouse Bone Marrow-Derived Macrophages

The Study of Cellular and Molecular Mechanism of the Combination Therapy Using Gukangling Decoction and Technetium[99tc] Methylene Diphosphonate for Glucocorticoid-Induced Osteoporosis

The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages

LDC000067 Suppresses RANKL-induced Osteoclastogenesis in Vitro and Prevents LPS-induced Osteolysis in Vivo.

LY900009 Regulates&nbsp;RANKL-Induced Osteoclast Formation and&nbsp;LPS-Induced Bone Resorption